Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FGFR3 Gene Alteration”

24 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 24 results

Testing effectiveness (Phase 2)Ended earlyNCT02952573
What this trial is testing

Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement

Who this might be right for
Multiple MyelomaRelapsed/Refractory
University Health Network, Toronto 20
Early research (Phase 1)Looking for participantsNCT06915753
What this trial is testing

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Who this might be right for
Metastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, Adult+11 more
Tyra Biosciences, Inc 100
Testing effectiveness (Phase 2)Study completedNCT04919642
What this trial is testing

Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Who this might be right for
CholangiocarcinomaFGFR2 FusionFGFR2 Gene Mutation+2 more
TransThera Sciences (Nanjing), Inc. 55
Testing effectiveness (Phase 2)Looking for participantsNCT06995677
What this trial is testing

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Who this might be right for
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc 90
Not applicableStudy completedNCT00106977
What this trial is testing

Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)

Who this might be right for
CraniosynostosisMuenke Syndrome
National Human Genome Research Institute (NHGRI) 137
Large-scale testing (Phase 3)Looking for participantsNCT07218380
What this trial is testing

Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Who this might be right for
Carcinoma, Transitional CellUrinary Bladder NeoplasmsNeoplasm Metastasis
Eli Lilly and Company 450
Testing effectiveness (Phase 2)Study completedNCT01752920
What this trial is testing

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Who this might be right for
Solid Tumor
Basilea Pharmaceutica 119
Testing effectiveness (Phase 2)Ended earlyNCT01732107
What this trial is testing

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

Who this might be right for
Bladder Cancer
Noah Hahn, M.D. 13
Early research (Phase 1)Study completedNCT01004224
What this trial is testing

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3Squamous Lung Cancer With FGFR1 AmplificationBladder Cancer With FGFR3 Mutation or Fusion+3 more
Novartis Pharmaceuticals 208
Not applicableEnded earlyNCT05052372
What this trial is testing

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Who this might be right for
Bladder CancerUrothelial CarcinomaTransitional Cell Carcinoma+10 more
xCures 2
Large-scale testing (Phase 3)Study completedNCT02965378
What this trial is testing

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR2 Gene Amplification+5 more
SWOG Cancer Research Network 43
Testing effectiveness (Phase 2)Study completedNCT02272998
What this trial is testing

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Who this might be right for
Malignant Neoplasm
Sameek Roychowdhury 22
Testing effectiveness (Phase 2)Ended earlyNCT02706691
What this trial is testing

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Who this might be right for
FGFR Gene AmplificationFGFR1 Gene AmplificationFGFR2 Gene Amplification+7 more
University of Chicago 1
Testing effectiveness (Phase 2)UnknownNCT04096417
What this trial is testing

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR1 Gene Translocation+16 more
Academic and Community Cancer Research United 14
Testing effectiveness (Phase 2)Looking for participantsNCT07265947
What this trial is testing

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

Who this might be right for
Low Grade Upper Tract Urothelial Carcinoma
Tyra Biosciences, Inc 230
Testing effectiveness (Phase 2)Active Not RecruitingNCT04917809
What this trial is testing

Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Who this might be right for
Bladder CancerRecurrent Bladder CancerFGFR3 Gene Mutation
Memorial Sloan Kettering Cancer Center 20
Not applicableUnknownNCT04921553
What this trial is testing

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

Who this might be right for
CancerCancer MetastaticNTRK Gene Fusion Overexpression+13 more
Centre Leon Berard 500
Not applicableUnknownNCT00126958
What this trial is testing

Cost-Effectiveness in Bladder Cancer

Who this might be right for
Bladder Cancer
Erasmus Medical Center 500
Not applicableStudy completedNCT00001754
What this trial is testing

Study of Skeletal Disorders and Short Stature

Who this might be right for
Developmental Bone DiseaseDwarfismSkeletal Dysplasias
National Human Genome Research Institute (NHGRI) 600
Testing effectiveness (Phase 2)WithdrawnNCT05222165
What this trial is testing

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

Who this might be right for
Advanced Solid TumorCNS TumorRecurrent WHO Grade II Glioma
Helsinn Healthcare SA
Load More Results